Assays for the presence of a mutant EGF receptor

US5710010A · kind A · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• Duke University · US

Inventors

• Bert Vogelstein · Baltimore, US
• Darell Bigner · Mebane, US

Key dates

• Filing date: Jun 2, 1995
• Grant date: Jan 20, 1998
• Expiry date: Jun 2, 2015

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/812
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The epidermal growth factor receptor (EGFR) gene is amplified in 40% of malignant gliomas and the amplified genes are frequently rearranged. The genetic alterations associated with these rearrangements are characterized in five malignant gliomas. In one tumor, the rearrangement resulted in the deletion of most of the extracytoplasmic domain of the receptor, resulting in a hybrid mRNA between new sequences and the truncated EGFR. The predicted amino acid sequence of the protein from this tumor was remarkably similar to that described for several viral erb-B oncogenes. Four other tumors were noted to have internal deletions of the EGF receptor gene. These rearrangements brought about in-frame deletions affecting either of two cysteine-rich domains in the extracytoplasmic portion of the molecule. The clonal nature of these alterations, and the fact that identical alterations were seen in more than one tumor, suggests a role for these mutant receptor proteins in tumorigenesis. Furthermore, these studies document the existence of tumor specific cell molecules resulting from somatic mutation.